There’s a lot of buzz about the popular GLP-1 weight loss drugs after President Donald Trump announced this week a deal with Novo Nordisk and Eli Lilly to lower the prices for Wegovy and Zepbound.
Dr. Naomi Parrella is the Chief of Lifestyle medicine at Rush University and an obesity medicine specialist.
She joined the WGN Evening News to talk more about the drugs and the announcement.
Sign up for our Medical Watch newsletter. This daily update includes important information from WGN’s Dina Bair and the Med Watch team, including, the latest updates from health organizations, in-depth reporting on advancements in medical technology and treatments, as well as personal features related to people in the medical field. Sign up here.
Want more insights? Join Working Title - our career elevating newsletter and get the future of work delivered weekly.
